Oculis CEO delivers updates on OCS-01 eye drop trials for DME


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Riad Sherif, MD, CEO of Oculis, discusses the company’s two phase 3 clinical trials for the OCS-01 eye drop.

OCS-01 is the first eye drop to be investigated for the treatment of diabetic macular edema, he said.

“I would like to thank all of our investigators who are helping and contributing to the DIAMOND (Diabetic macular edema patients on a drop) trial,” Sherif said. “I am also happy to say that our second phase 3 trial, OPTIMIZE-2 (Once daily post-ocular treatment or inflammation and pain to minimize drops) is still ongoing.”

Source link

error: Content is protected !!